Schedule 13G ownership disclosure
Celldex Therapeutics Inc
COMMON STOCK · CUSIP: 15117B202
Event date: 2025-09-30
- Filing-level shares
- 2,382,701
- Percent of class
- 3.6%
- T. Rowe Price Associates, Inc.
Shares: 2,382,701 · Class: 3.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000800
- Form type
- SCHEDULE 13G/A
- Filer
- Celldex Therapeutics, Inc.
- CIK
- CIK 744218
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership